RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aldeyra Therapeutics Stock

Aldeyra Therapeutics Employees 2024

Aldeyra Therapeutics Employees

11

Ticker

ALDX

ISIN

US01438T1060

WKN

A111X8

In 2024, Aldeyra Therapeutics employed 11 people, a 0% change from the 11 number of employees in the previous year.

Aldeyra Therapeutics Aktienanalyse

What does Aldeyra Therapeutics do?

Aldeyra Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for serious eye and immune system diseases. The company was founded in 2004 by Dr. Tod B. Zimmerman and is headquartered in Lexington, Massachusetts. The history of Aldeyra Therapeutics began with the discovery of a new approach to treating inflammatory diseases. The company identified a new class of compounds known as aldehyde binding agents that help reduce the effects of chronic inflammation. In 2013, Aldeyra went public and raised $15 million to advance the development of its products. Aldeyra Therapeutics' business model focuses on building a portfolio of therapies for serious diseases. The company leverages its expertise in drug discovery, development, and commercialization to develop new therapies targeting rare diseases and unmet clinical needs. Aldeyra Therapeutics is divided into two main areas: ophthalmology and immunology. In the ophthalmology field, the company focuses on developing therapies for the treatment of dry eye, pterygium, conjunctivitis, and other eye diseases. In the immunology field, the company aims to develop therapies for immune-related diseases such as asthma, chronic obstructive pulmonary disease (COPD), autoimmune diseases, and others. One key product of Aldeyra Therapeutics is the drug reproxalap, which was developed to halt the progression of dry eye disease. Reproxalap is an aldehyde binding agent designed to help reduce inflammation, pain, and redness in patients with dry eye. The company plans to conduct further clinical trials for reproxalap to facilitate its submission for approval to the US Food and Drug Administration (FDA). Another product in the immunology field is ADX-1612, an aldehyde binding agent targeting the treatment of asthma. The clinical trials are still in the early phases, but preliminary data provide hope that ADX-1612 could become an important component of asthma therapy in the future. Aldeyra Therapeutics does not work alone. The company has partnerships with other biotech or pharmaceutical companies, such as in the development of therapeutics for rare immunological and eye diseases or the development of diagnostic tests for a specific eye disease. The company hopes that its research and development efforts will ultimately help improve the lives of people with serious diseases. Although there is a risk of setbacks in the development of new therapies, it is hoped that Aldeyra Therapeutics will find new ways in the future to address the unmet needs of patients in need. Aldeyra Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Aldeyra Therapeutics's Employee Base

Aldeyra Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Aldeyra Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Aldeyra Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Aldeyra Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Aldeyra Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Aldeyra Therapeutics stock

How many employees does Aldeyra Therapeutics have this year?

Aldeyra Therapeutics has 11 undefined employees this year.

How many employees did Aldeyra Therapeutics have compared to the previous year?

Compared to the previous year, Aldeyra Therapeutics had 0% more employees.

What impact did the number of employees have on the company Aldeyra Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Aldeyra Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Aldeyra Therapeutics?

The number of employees can also have an impact on investors of Aldeyra Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Aldeyra Therapeutics affect the company?

An increase in equity of Aldeyra Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Aldeyra Therapeutics's equity affect the company?

A reduction in equity of Aldeyra Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Aldeyra Therapeutics?

Some factors that can influence the equity of Aldeyra Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Aldeyra Therapeutics so important for investors?

The equity of Aldeyra Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Aldeyra Therapeutics influence the company?

The number of employees at Aldeyra Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Aldeyra Therapeutics evolved in recent years?

In recent years, the number of employees at Aldeyra Therapeutics has changed by 0.

How many employees does Aldeyra Therapeutics currently have?

Aldeyra Therapeutics currently has 11 undefined employees.

Why is the number of employees important for investors of Aldeyra Therapeutics?

The number of employees is important for investors of Aldeyra Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Aldeyra Therapeutics take to change the number of employees?

To change the number of employees, Aldeyra Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Aldeyra Therapeutics pay?

Over the past 12 months, Aldeyra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aldeyra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aldeyra Therapeutics?

The current dividend yield of Aldeyra Therapeutics is .

When does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aldeyra Therapeutics?

Aldeyra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aldeyra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aldeyra Therapeutics located?

Aldeyra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aldeyra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aldeyra Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Aldeyra Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Aldeyra Therapeutics in the year 2023?

In the year 2023, Aldeyra Therapeutics distributed 0 USD as dividends.

In which currency does Aldeyra Therapeutics pay out the dividend?

The dividends of Aldeyra Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aldeyra Therapeutics

Our stock analysis for Aldeyra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aldeyra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.